Results 41 to 50 of about 8,947 (130)

Clinicopathological Associations of Plasma Cell‐Rich Rejection in Pediatric Liver Transplant Recipients

Pediatric Transplantation, Volume 30, Issue 7, July 2026.
Plasma cell‐rich rejection (PCRR) occurred in 15.3% of pediatric liver transplant recipients. PCRR was associated with recurrent rejection, severe rejection, central perivenulitis, ANA positivity, and chronic rejection. PCRR was not independently associated with mortality.
R. Gemell, C. Hajinicolaou, M. Hale, P. Walabh   +3 more
wiley   +1 more source

Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin

Immunity, Inflammation and Disease, 2021
Objective Cytomegalovirus (CMV) infections are correlated with complications following heart transplantation (HTx) and impaired outcome. The impact of a serologic mismatch between donor and recipient and the necessity of prophylactic virostatic ...
Moritz B. Immohr, Payam Akhyari, Charlotte Böttger, Arash Mehdiani, Hannan Dalyanoglu, Ralf Westenfeld, Daniel Oehler, Igor Tudorache, Hug Aubin, Artur Lichtenberg, Udo Boeken   +10 more
doaj   +1 more source

Successful Management of Persistent DRESS with Tofacitinib: Two Case Reports

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marc Hernández‐Santacana, Ignasi Martí‐Martí, Victoria Amat‐Samaranch, Irene Fuertes de Vega, Priscila Giavedoni, José M. Mascaró Jr   +5 more
wiley   +1 more source

Outcomes of a Routine Screening Protocol to Prevent Metamycoplasma and Ureaplasma Infection in Lung Transplant Recipients

Transplant Infectious Disease, Volume 28, Issue 4, July/August 2026.
This study analyzed outcomes of an early Mollicute (Mycoplasma hominis and Ureaplasma spp.) screening protocol using BAL PCR with preemptive treatment and ammonia monitoring in lung transplant recipients. This appears to be a practical and reasonably effective approach for preventing early Mollicute infection and hyperammonemia syndrome.
Lalithaa Thirunavukarasu Murugan, Anika Sasidharan Nair, Marie M. Budev, Maureen Converse, Nabin K. Shrestha, Christine E. Koval   +5 more
wiley   +1 more source

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system

Frontiers in Pharmacology
BackgroundMaribavir and valganciclovir are pharmacotherapeutic options utilized in the management of cytomegalovirus (CMV) infection post-transplantation.
Haolin Teng, Shengnan Zhang, Jinyu Yu, Faping Li   +3 more
doaj   +1 more source

Bridging the Gap Between General and Transplant Infectious Disease Practice

Transplant Infectious Disease, Volume 28, Issue 4, July/August 2026.
ABSTRACT The population of iatrogenic immunocompromised individuals is steadily rising as we continue to improve in our ability to manage diseases, including cancer, autoimmune disease, and end‐organ dysfunction, with increasing access to novel agents and transplantation.
Jeremey Walker, Emily Eichenberger, Steven Pergam, Maricar Malinis, Andrea J. Zimmer   +4 more
wiley   +1 more source

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis

Clinical Ophthalmology, 2012
Yoshiaki Kabata1, Genichiro Takahashi1, Hiroshi Tsuneoka21Department of Ophthalmology, Jikei University School of Medicine, Katsushika Medical Center, Katsushika, Tokyo, Japan; 2Department of Ophthalmology, Jikei University School of Medicine, Minato ...
Kabata Y, Takahashi G, Tsuneoka H
doaj  

European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B‐Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community‐Based Centers and for Outpatient Step‐Up Dosing

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Safe outpatient delivery of B‐cell maturation antigen–targeting bispecific antibodies (BCMA‐BsAbs) in multiple myeloma (MM) is challenging, particularly during step‐up dosing (SUD). Standardized guidance for European community practice is limited.
María‐Victoria Mateos, Elena Zamagni, Massimo Gentile, Rachel Hall, Florence Lachenal, Mónica López Riñon, Rakesh Popat, Christof Scheid, Thomas Wolff, Isabel Perez‐Cruz, Mohamad Mohty   +10 more
wiley   +1 more source

A case of secretory azoospermia: is valganciclovir responsible?

Basic and Clinical Andrology
Background Valganciclovir, the prodrug of ganciclovir, is an antiviral agent targeting herpes viruses. It is indicated for the prophylaxis or treatment of cytomegalovirus infections in immunocompromised patients. Pre-clinical studies state ganciclovir as
Louise Michenaud, Marion Lapoirie, Eloïse Fraison, Bruno Salle-Leyris-de-Campredon, Ingrid Plotton, Sandrine Giscard-d’Estaing   +5 more
doaj   +1 more source

Diagnostic and Therapeutic Dilemmas in Recurrent Pulmonary Alveolar Proteinosis After Bilateral Lung Transplantation

Respirology Case Reports, Volume 14, Issue 6, June 2026.
Pulmonary alveolar proteinosis (PAP) is an ultra‐rare lung disease that can recur even years after bilateral lung transplantation, as in this 73‐year‐old man whose diagnosis was delayed by PAS‐negative BAL and overlapping opportunistic infections (Nocardia, MAC, Aspergillus). Despite initially normal post‐transplant spirometry, he developed progressive
Omar Lopez, Deven Gupta, Shreya Podder, Ajay Wagh   +3 more
wiley   +1 more source